Hepatitis C genotype 4: The past, present, and future

World Journal of Hepatology

Volumn 7, Issue 28, 2015, Pages 2792-2810

  Abdel Ghaffar, Tawhida Y ^a,b   Sira, Mostafa M ^c   El Naghi, Suzan ^b,d  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b Yassin Abdelghaffar Charity Center for Liver Disease and Research   (Egypt)

^c MENOUFIA UNIVERSITY   (Egypt)

^d NATIONAL HEPATOLOGY AND TROPICAL MEDICINE RESEARCH INSTITUTE   (Egypt)

Author keywords

Direct acting antivirals; Genotypes; Hepatitis C virus; Hepatitis C virus vaccine; Pegylated interferon; Ribavirin; Transmission

Indexed keywords

EID: 84949550161     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i28.2792     Document Type: Article

References (201)

1. Houghton M. Discovery of the hepatitis C virus. Liver Int 2009; 29 Suppl 1: 82-88 [PMID: 19207970 DOI: 10.1111/j.1478-3231.2008.01925.x]
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567 [PMID: 16122679 DOI: 10.1016/S1473-3099(05)70216-4]
3. WHO. Hepatitis C Fact sheet No. 164, 2014. [Accessed 2015 May 1]. Available from: URL: http://www.who.int/mediacentre/factsheets/fs164/en/
4. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]
5. Preciado MV, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L, Vazquez-Chacon C, Martinez-Guarneros A, Carpio-Pedroza JC, Fonseca-Coronado S, Cruz-Rivera M. Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. World J Gastroenterol 2014; 20: 15992-16013 [PMID: 25473152 DOI: 10.3748/wjg.v20.i43.15992]
6. Tang H, Grisé H. Cellular and molecular biology of HCV infection and hepatitis. Clin Sci (Lond) 2009; 117: 49-65 [PMID: 19515018 DOI: 10.1042/CS20080631]
7. Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, van der Meer JT, Schinkel J. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 2011; 25: F21-F27 [PMID: 21857492 DOI: 10.1097/QAD.0b013e32834 bac44]
8. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-327 [PMID: 24115039 DOI: 10.1002/hep.26744]
9. Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol 2004; 85: 3173-3188 [PMID: 15483230 DOI: 10.1099/vir.0.80401-0]
10. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87 [PMID: 25069599 DOI: 10.1002/hep.27259]
11. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996; 125: 634-639 [PMID: 8849147]
12. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74(Pt 11): 2391-2399 [PMID: 8245854]
13. Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014; 39: 137-147 [PMID: 24251930 DOI: 10.1111/apt.12551]
14. Martial J, Morice Y, Abel S, Cabié A, Rat C, Lombard F, Edouard A, Pierre-Louis S, Garsaud P, Béra O, Chout R, Gordien E, Deny P, Césaire R. Hepatitis C virus (HCV) genotypes in the Caribbean island of Martinique: evidence for a large radiation of HCV-2 and for a recent introduction from Europe of HCV-4. J Clin Microbiol 2004; 42: 784-791 [PMID: 14766854]
15. Raghuraman S, Abraham P, Sridharan G, Daniel HD, Ramakrishna BS, Shaji RV. HCV genotype 4--an emerging threat as a cause of chronic liver disease in Indian (south) patients. J Clin Virol 2004; 31: 253-258 [PMID: 15494265 DOI: 10.1016/j.jcv.2004.03.019]
16. Singh S, Malhotra V, Sarin SK. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. Indian J Med Res 2004; 119: 145-148 [PMID: 15147119]
17. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45-S57 [PMID: 25086286 DOI: 10.1016/j.jhep.2014.07.027]
18. El-Zanaty F, Way A. Demographic and Health Survey. Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International, 2009. Available from: URL: http://dhsprogram.com/pubs/pdf/FR220/FR220.pdf
19. Baatarkhuu O, Kim do Y, Ahn SH, Nymadawa P, Dahgwahdorj Y, Shagdarsuren M, Park JY, Choi JW, Oyunbileg J, Oyunsuren T, Han KH. Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a populationbased nationwide study. Liver Int 2008; 28: 1389-1395 [PMID: 18647237 DOI: 10.1111/j.1478-3231.2008.01820.x]
20. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012; 19: 560-567 [PMID: 22762140 DOI: 10.1111/j.1365-2893.2011.01576.x]
21. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis 2000; 182: 698-707 [PMID: 10950762 DOI: 10.1086/315786]
22. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balik I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 Suppl 1: 34-59 [PMID: 24713005 DOI: 10.1111/jvh.12248]
23. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-891 [PMID: 10752705]
24. Rao MR, Naficy AB, Darwish MA, Darwish NM, Schisterman E, Clemens JD, Edelman R. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect Dis 2002; 2: 29 [PMID: 12464161]
25. El Sherbini A, Mohsen SA, Hasan W, Mostafa S, El Gohary K, Moneib A, Abaza AH. The peak impact of an Egyptain outbreak of hepatitis C virus: has it passed or has not yet occurred? Liver Int 2007; 27: 876-877 [PMID: 17617132 DOI: 10.1111/j.1478-3231.2007.01501.x]
26. Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, Madkour S, Mikhail NN, Anwar W, Strickland GT, Fix AD, Sallam I. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001; 33: 248-253 [PMID: 11124843 DOI: 10.1053/jhep.2001.20797]
27. Medhat A, Shehata M, Magder LS, Mikhail N, Abdel-Baki L, Nafeh M, Abdel-Hamid M, Strickland GT, Fix AD. Hepatitis c in a community in Upper Egypt: risk factors for infection. Am J Trop Med Hyg 2002; 66: 633-638 [PMID: 12201604]
28. Arafa N, El Hoseiny M, Rekacewicz C, Bakr I, El-Kafrawy S, El Daly M, Aoun S, Marzouk D, Mohamed MK, Fontanet A. Changing pattern of hepatitis C virus spread in rural areas of Egypt. J Hepatol 2005; 43: 418-424 [PMID: 16019104 DOI: 10.1016/j.jhep.2005.03.021]
29. Darwish MA, Faris R, Darwish N, Shouman A, Gadallah M, El-Sharkawy MS, Edelman R, Grumbach K, Rao MR, Clemens JD. Hepatitis c and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. Am J Trop Med Hyg 2001; 64: 147-153 [PMID: 11442209]
30. Mohamed MK, Magder LS, Abdel-Hamid M, El-Daly M, Mikhail NN, Abdel-Aziz F, Medhat A, Thiers V, Strickland GT. Transmission of hepatitis C virus between parents and children. Am J Trop Med Hyg 2006; 75: 16-20 [PMID: 16837701]
31. AbdulQawi K, Youssef A, Metwally MA, Ragih I, AbdulHamid M, Shaheen A. Prospective study of prevalence and risk factors for hepatitis C in pregnant Egyptian women and its transmission to their infants. Croat Med J 2010; 51: 219-228 [PMID: 20564765]
32. Shebl FM, El-Kamary SS, Saleh DA, Abdel-Hamid M, Mikhail N, Allam A, El-Arabi H, Elhenawy I, El-Kafrawy S, El-Daly M, Selim S, El-Wahab AA, Mostafa M, Sharaf S, Hashem M, Heyward S, Stine OC, Magder LS, Stoszek S, Strickland GT. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol 2009; 81: 1024-1031 [PMID: 19382251 DOI: 10.1002/jmv.21480]
33. Yeung CY, Lee HC, Chan WT, Jiang CB, Chang SW, Chuang CK. Vertical transmission of hepatitis C virus: Current knowledge and perspectives. World J Hepatol 2014; 6: 643-651 [PMID: 25276280 DOI: 10.4254/wjh.v6.i9.643]
34. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013; 13: 288 [PMID: 23799878 DOI: 10.1186/1471-2334-13-288]
35. Abdelwahab MS, El-Raziky MS, Kaddah NA, Abou-Elew HH. Prevalence of hepatitis C virus infection and human immunodeficiency virus in a cohort of Egyptian hemophiliac children. Ann Saudi Med 2012; 32: 200-202 [PMID: 22366833]
36. Barakat SH, El-Bashir N. Hepatitis C virus infection among healthy Egyptian children: prevalence and risk factors. J Viral Hepat 2011; 18: 779-784 [PMID: 21992795 DOI: 10.1111/j.1365-2893.2010.01381.x]
37. El-Karaksy H, Anwar GH, El-Raziky MS, El-Hawary M, Hashem M, El-Sayed R, El-Shabrawi M, Mohsen N, Fouad H, Esmat G. Anti-HCV prevalence among diabetic and non-diabetic Egyptian children. Curr Diabetes Rev 2010; 6: 388-392 [PMID: 20879976]
38. Breban R, Doss W, Esmat G, Elsayed M, Hellard M, Ayscue P, Albert M, Fontanet A, Mohamed MK. Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat 2013; 20: 294-296 [PMID: 23490375 DOI: 10.1111/j.1365-2893.2012.01650.x]
39. Saleh DA, Shebl FM, El-Kamary SS, Magder LS, Allam A, Abdel-Hamid M, Mikhail N, Hashem M, Sharaf S, Stoszek SK, Strickland GT. Incidence and risk factors for community-acquired hepatitis C infection from birth to 5 years of age in rural Egyptian children. Trans R Soc Trop Med Hyg 2010; 104: 357-363 [PMID: 20153495 DOI: 10.1016/j.trstmh.2010.01.009]
40. Mostafa A, Taylor SM, el-Daly M, el-Hoseiny M, Bakr I, Arafa N, Thiers V, Rimlinger F, Abdel-Hamid M, Fontanet A, Mohamed MK. Is the hepatitis C virus epidemic over in Egypt? Incidence and risk factors of new hepatitis C virus infections. Liver Int 2010; 30: 560-566 [PMID: 20141592 DOI: 10.1111/j.1478-3231.2009.02204. x]
41. Reker C, Islam KM. Risk factors associated with high prevalence rates of hepatitis C infection in Egypt. Int J Infect Dis 2014; 25: 104-106 [PMID: 24865321 DOI: 10.1016/j.ijid.2014.02.003]
42. Centers for Disease Control and Prevention (CDC). Progress toward prevention and control of hepatitis C virus infection--Egypt, 2001-2012. MMWR Morb Mortal Wkly Rep 2012; 61: 545-549 [PMID: 22832935]
43. Esmat G, Hashem M, El-Raziky M, El-Akel W, El-Naghy S, El-Koofy N, El-Sayed R, Ahmed R, Atta-Allah M, Hamid MA, El-Kamary SS, El-Karaksy H. Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. Liver Int 2012; 32: 449-456 [PMID: 22098096 DOI: 10.1111/j.1478-3231.2011.02643.x]
44. Kandeel AM, Talaat M, Afifi SA, El-Sayed NM, Abdel Fadeel MA, Hajjeh RA, Mahoney FJ. Case control study to identify risk factors for acute hepatitis C virus infection in Egypt. BMC Infect Dis 2012; 12: 294 [PMID: 23145873 DOI: 10.1186/1471-2334-12-294]
45. Paez Jimenez A, Sharaf Eldin N, Rimlinger F, El-Daly M, El-Hariri H, El-Hoseiny M, Mohsen A, Mostafa A, Delarocque-Astagneau E, Abdel-Hamid M, Fontanet A, Mohamed MK, Thiers V. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut 2010; 59: 1554-1560 [PMID: 20947889 DOI: 10.1136/gut.2009.194266]
46. Plancoulaine S, Mohamed MK, Arafa N, Bakr I, Rekacewicz C, Trégouët DA, Obach D, El Daly M, Thiers V, Féray C, Abdel-Hamid M, Abel L, Fontanet A. Dissection of familial correlations in hepatitis C virus (HCV) seroprevalence suggests intrafamilial viral transmission and genetic predisposition to infection. Gut 2008; 57: 1268-1274 [PMID: 18480169 DOI: 10.1136/gut.2007.140681]
47. Saleh DA, Shebl F, Abdel-Hamid M, Narooz S, Mikhail N, El-Batanony M, El-Kafrawy S, El-Daly M, Sharaf S, Hashem M, El-Kamary S, Magder LS, Stoszek SK, Strickland GT. Incidence and risk factors for hepatitis C infection in a cohort of women in rural Egypt. Trans R Soc Trop Med Hyg 2008; 102: 921-928 [PMID: 18514243 DOI: 10.1016/j.trstmh.2008.04.011]
48. Zahran KM, Badary MS, Agban MN, Abdel Aziz NH. Pattern of hepatitis virus infection among pregnant women and their newborns at the Women's Health Center of Assiut University, Upper Egypt. Int J Gynaecol Obstet 2010; 111: 171-174 [PMID: 20708181 DOI: 10.1016/j.ijgo.2010.06.013]
49. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-782 [PMID: 10706572 DOI: 10.1002/hep.510310332]
50. Centers for Disease Contro and Provention. Disease Burden from Viral Hepatitis A, B, and C in the United States. 2015. Available from: URL: http://www.cdc.gov/hepatitis/Statistics/index.htm
51. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol 2008; 49: 625-633 [PMID: 18706735 DOI: 10.1016/j.jhep.2008.07.005]
52. McHutchison JG. Understanding hepatitis C. Am J Manag Care 2004; 10: S21-S29 [PMID: 15084064]
53. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46 [PMID: 12407575 DOI: 10.1053/jhep.2002.36806]
54. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-88 [PMID: 12851873]
55. Yoshikawa M, Morimoto Y, Shiroi A, Yoshiji H, Kuriyama S, Fukui H. Spontaneous elimination of serum HCV-RNA after total gastrectomy for early gastric cancer in a patient with chronic hepatitis C. Am J Gastroenterol 2001; 96: 922-923 [PMID: 11280585 DOI: 10.1111/j.1572-0241.2001.03650.x]
56. Fujisawa T, Komatsu H, Inui A, Miyagawa Y, Onoue M, Sekine I, Yokota S, Hanada R, Yamamoto K, Inui M. Spontaneous remission of chronic hepatitis C in children. Eur J Pediatr 1997; 156: 773-776 [PMID: 9365066]
57. Iorio R, Giannattasio A, Sepe A, Terracciano LM, Vecchione R, Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis 2005; 41: 1431-1437 [PMID: 16231253 DOI: 10.1086/497141]
58. Vogt M, Lang T, Frösner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, Langer B, Meisner H, Hess J. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866-870 [PMID: 10498458 DOI: 10.1056/NEJM199909163411202]
59. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012; 18: 99-104 [PMID: 22253515 DOI: 10.3748/wjg.v18.i2.99]
60. Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, Babudieri S, Toti M, Francavilla R, Ancarani F, Antonucci G, Scotto G, Di Marco V, Pastore G, Stroffolini T. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 2006; 43: 1154-1159 [PMID: 17029134 DOI: 10.1086/507640]
61. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI: 10.1038/nature08463]
62. El-Awady MK, Mostafa L, Tabll AA, Abdelhafez TH, Bader El Din NG, Zayed N, Shenawy RE, El Abd Y, Hasan RM, Zaghlol H, El Khayat H, Abdel Aziz AO. Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease. Hepat Mon 2012; 12: 271-277 [PMID: 22690235 DOI: 10.5812/hepatmon.835]
63. Ruiz-Extremera A, Muñoz-Gámez JA, Salmerón-Ruiz MA, de Rueda PM, Quiles-Pérez R, Gila-Medina A, Casado J, Belén Martín A, Sanjuan-Nuñez L, Carazo A, Pavón EJ, Ocete-Hita E, León J, Salmerón J. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011; 53: 1830-1838 [PMID: 21413051 DOI: 10.1002/hep.24298]
64. Danta M, Semmo N, Fabris P, Brown D, Pybus OG, Sabin CA, Bhagani S, Emery VC, Dusheiko GM, Klenerman P. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008; 197: 1558-1566 [PMID: 18419344 DOI: 10.1086/587843]
65. Schnuriger A, Dominguez S, Guiguet M, Harfouch S, Samri A, Ouazene Z, Slama L, Simon A, Valantin MA, Thibault V, Autran B. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 2009; 23: 2079-2089 [PMID: 19710595 DOI: 10.1097/QAD.0b013e328330ed24]
66. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642 [PMID: 16697727 DOI: 10.1053/j.gastro.2006.03.014]
67. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, Huraux JM, Devergie B, Vidaud M, Opolon P, Poynard T. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-872 [PMID: 9500720 DOI: 10.1002/hep.510270333]
68. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-666 [PMID: 19665246 DOI: 10.1016/j.jhep.2009.05.016]
69. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014; 60: 98-105 [PMID: 24615981 DOI: 10.1002/hep.27095]
70. Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, Ganne-Carrie N, Grando-Lemaire V, Trinchet JC, Gordien E, Vicaut E, Baghad I, Beaugrand M. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011; 18: e516-e522 [PMID: 21914071 DOI: 10.1111/j.1365-2893.2011.01441.x]
71. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593 [PMID: 23268517 DOI: 10.1001/jama.2012.144878]
72. Chiba T, Matsuzaki Y, Abei M, Shoda J, Aikawa T, Tanaka N, Osuga T. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996; 31: 552-558 [PMID: 8844477]
73. Narciso-Schiavon JL, Schiavon LL, Carvalho-Filho RJ, Freire FC, Cardoso JR, Bordin JO, Silva AE, Ferraz ML. Anti-hepatitis C virus-positive blood donors: are women any different? Transfus Med 2008; 18: 175-183 [PMID: 18598280 DOI: 10.1111/j.1365-3148.2008.00859.x]
74. Terrault NA, Im K, Boylan R, Bacchetti P, Kleiner DE, Fontana RJ, Hoofnagle JH, Belle SH. Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin Gastroenterol Hepatol 2008; 6: 1403-1411 [PMID: 19081528 DOI: 10.1016/j.cgh.2008.08.006]
75. Abdel-Hamid M, El-Daly M, Molnegren V, El-Kafrawy S, Abdel-Latif S, Esmat G, Strickland GT, Loffredo C, Albert J, Widell A. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 2007; 88: 1526-1531 [PMID: 17412982 DOI: 10.1099/vir.0.82626-0]
76. Minola E, Prati D, Suter F, Maggiolo F, Caprioli F, Sonzogni A, Fraquelli M, Paggi S, Conte D. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002; 99: 4588-4591 [PMID: 12036892 DOI: 10.1182/blood-2001-12-0192]
77. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832 [PMID: 9121257]
78. Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol 2004; 19: 1357-1362 [PMID: 15610308 DOI: 10.1111/j.1440-1746.2004.03463.x]
79. Wiese M, Grüngreiff K, Güthoff W, Lafrenz M, Oesen U, Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. J Hepatol 2005; 43: 590-598 [PMID: 16237783]
80. Yosry A, Fouad R, Mahmoud S, El-Raziky MS, El-Hennawy A, Ghoneim MA. The association of HLA class II DR B1 alleles with HCV infection in Egyptian children. Arab J Gastroenterol 2011; 12: 25-28 [PMID: 21429451 DOI: 10.1016/j.ajg.2011.01.007]
81. Tagger A, Donato F, Ribero ML, Chiesa R, Portera G, Gelatti U, Albertini A, Fasola M, Boffetta P, Nardi G. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999; 81: 695-699 [PMID: 10328218]
82. Hézode C, Lonjon I, Roudot-Thoraval F, Mavier JP, Pawlotsky JM, Zafrani ES, Dhumeaux D. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003; 52: 126-129 [PMID: 12477773]
83. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009; 50: 1360-1369 [PMID: 19676128 DOI: 10.1002/hep.23162]
84. Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, Takahashi I, Chayama K. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17: 846-854 [PMID: 18398026 DOI: 10.1158/1055-9965.EPI-07-2806]
85. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007; 109: 2490-2496 [PMID: 17487861 DOI: 10.1002/cncr.22701]
86. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125: 1695-1704 [PMID: 14724822]
87. Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, Kuo YH, Tsai MC, Lu SN, Lee CM. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 2010; 16: 2265-2271 [PMID: 20458764]
88. Hu SX, Kyulo NL, Xia VW, Hillebrand DJ, Hu KQ. Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients. J Clin Gastroenterol 2009; 43: 758-764 [PMID: 19238091 DOI: 10.1097/MCG.0b013e31818be17c]
89. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-1862 [PMID: 18506898 DOI: 10.1002/hep.22251]
90. Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003; 30: 137-144 [PMID: 12957298]
91. Deng LP, Gui XE, Zhang YX, Gao SC, Yang RR. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2009; 15: 996-1003 [PMID: 19248201]
92. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 1979-1991 [PMID: 18784461 DOI: 10.1097/QAD.0b013e32830e6d51]
93. Germani G, Tsochatzis E, Papastergiou V, Burroughs AK. HCV in liver transplantation. Semin Immunopathol 2013; 35: 101-110 [PMID: 22829333 DOI: 10.1007/s00281-012-0329-5]
94. Meriden Z, Forde KA, Pasha TL, Hui JJ, Reddy KR, Furth EE, Wells RG. Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2010; 8: 289-296, 296.e1-8 [PMID: 19913638 DOI: 10.1016/j.cgh.2009.10.034]
95. Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol 2012; 2012: 871401 [PMID: 22988469 DOI: 10.1155/2012/871401]
96. Ko HM, Hernandez-Prera JC, Zhu H, Dikman SH, Sidhu HK, Ward SC, Thung SN. Morphologic features of extrahepatic manifestations of hepatitis C virus infection. Clin Dev Immunol 2012; 2012: 740138 [PMID: 22919404 DOI: 10.1155/2012/740138]
97. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495 [PMID: 1383822 DOI: 10.1056/NEJM199211193272104]
98. Sène D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 2004; 19: 357-381 [PMID: 15554428]
99. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis 2008; 3: 25 [PMID: 18796155 DOI: 10.1186/1750-1172-3-25]
100. Pozzato G, Mazzaro C, Crovatto M, Modolo ML, Ceselli S, Mazzi G, Sulfaro S, Franzin F, Tulissi P, Moretti M. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994; 84: 3047-3053 [PMID: 7949176]
101. Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008; 20: 23-28 [PMID: 18281853 DOI: 10.1097/BOR.0b013e3282f1330c]
102. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831-844 [PMID: 18814931 DOI: 10.1016/j.jhep.2008.08.006]
103. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, Thomas DL. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38: 50-56 [PMID: 12829986 DOI: 10.1053/jhep.2003.50291]
104. Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, Henrion J, Mathurin P, Serfaty L. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011; 55: 1187-1194 [PMID: 21703195 DOI: 10.1016/j.jhep.2011.03.010]
105. Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci 2009; 54: 2699-2705 [PMID: 19148751 DOI: 10.1007/s10620-008-0683-2]
106. Younossi Z, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, Coate B, DeMasi R, Picchio G, Witek J. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology 2013; 58: 1897-1906 [PMID: 24382638 DOI: 10.1002/hep.26437]
107. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47: 1-39 [PMID: 9790221]
108. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. [Accessed 2015 Apr 29]. Available from: URL: http://hcvguidelines.org/full-report-view
109. Rose R, Markov PV, Lam TT, Pybus OG. Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation. Infect Genet Evol 2013; 20: 418-421 [PMID: 24140473 DOI: 10.1016/j.meegid.2013.09.029]
110. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759]
111. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 558-566 [PMID: 23070489 DOI: 10.7326/0003-4819-157-8-201210160-00006]
112. Centers for Disease Control and Prevention (CDC). Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013; 62: 362-365 [PMID: 23657112]
113. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 61: 373-395 [PMID: 24818984 DOI: 10.1016/j.jhep.2014.05.001]
114. Badizadegan K, Jonas MM, Ott MJ, Nelson SP, Perez-Atayde AR. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998; 28: 1416-1423 [PMID: 9794930 DOI: 10.1002/hep.510280534]
115. El-Hawary MA, El-Raziky MS, Esmat G, Soliman H, Abouzied A, El-Raziky M, El-Akel W, El-Sayed R, Shebl F, Shaheen AA, El-Karaksy H. Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. World J Gastroenterol 2007; 13: 2846-2851 [PMID: 17569121]
116. Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009; 16: 300-314 [PMID: 19254351 DOI: 10.1111/j.1365-2893.2009.01087.x]
117. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713 [PMID: 14698338]
118. Bonnard P, Elsharkawy A, Zalata K, Delarocque-Astagneau E, Biard L, Le Fouler L, Hassan AB, Abdel-Hamid M, El-Daly M, Gamal ME, El Kassas M, Bedossa P, Carrat F, Fontanet A, Esmat G. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt. J Viral Hepat 2015; 22: 245-253 [PMID: 25073725 DOI: 10.1111/jvh.12285]
119. Cortez KJ, Kottilil S. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis 2015; 6: 4-14 [PMID: 25553238 DOI: 10.1177/2040622314551934]
120. Irshad M, Ansari MA, Singh A, Nag P, Raghvendra L, Singh S, Badhal SS. HCV-genotypes: a review on their origin, global status, assay system, pathogenecity and response to treatment. Hepatogastroenterology 2010; 57: 1529-1538 [PMID: 21443116]
121. Varghese R, Al-Khaldi J, Asker H, Fadili AA, Al Ali J, Hassan FA. Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin. Hepatogastroenterology 2009; 56: 218-222 [PMID: 19453061]
122. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
123. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
124. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
125. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024 [PMID: 21916639 DOI: 10.1056/NEJMoa1014463]
126. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
127. Benhamou Y, Moussalli J, Ratziu V, Lebray P, De Backer K, De Meyer S, Ghys A, Luo D, Picchio GR, Beumont M. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. J Infect Dis 2013; 208: 1000-1007 [PMID: 23801602 DOI: 10.1093/infdis/jit274]
128. Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, Al-Ahdal MN, Mayet I, Khan MQ, Kessie G. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 568-574 [PMID: 15566506 DOI: 10.1111/j.1478-3231.2004.0976.x]
129. Esmat G, Mohamed MK, Abdel Hamid M, Zalata K, Khatab H, El Batanony M, Abouzied AM, El Raziky M, Shaheen AM, Ismail A, Strickland GT, Fix A, Sjogren M. The impact of steatosis on baseline characteristic and end of treatment response for chronic hepatitis (C) genotype 4 patients treated with interferon. J Hepato 2003; 38: 139 [DOI: 10.1016/s0168-8278(03)80743-2]
130. Shobokshi O, Serebour F, Skakni L, Tantawi A, Dinish T, Al Quaiz M, Sandokji A, Al-Kayyal B, Al Momen S, Akbar H, Ayoola A, Amer H, Hussein E, Khawaja F, Al-Jasser N. Efficacy of pegylated (40 KDA) IFN alfa-2a (PEGASYS) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. J Hepato 2002; 36 Supplement 1: 129 [DOI: 10.1016/S0168-8278(02)80462-7]
131. Thakeb F, Omar M, Bilharz T, Awady M, Isshak S. Randomized controlled trial of peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus-genotype 4 among Egyptian patients. Hepatology 2003; 38: 278A [DOI: 10.1002/hep.1840380504]
132. Diago M, Hadziayannus S, Bodenheimer H, Hassanein T, Uchman S, Marcellin P, Ramadori G, Delwaide J, Sedarati F. Optimized virological response in genotype 4 chrnoic hepatitis C patients treated with peginterferon alfa-2a (PEGASYS) in combination with ribavirin (RBV). Hepatology 2002; 36: 364A
133. El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005; 100: 2447-2452 [PMID: 16279899 DOI: 10.1111/j.1572-0241.2005.00253.x]
134. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA, Madwar MA. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858-866 [PMID: 15888797 DOI: 10.1136/gut.2004.057182]
135. Davies A, Singh KP, Shubber Z, Ducros P, Mills EJ, Cooke G, Ford N. Treatment outcomes of treatment-naïve Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts. PLoS One 2013; 8: e55373 [PMID: 23393570 DOI: 10.1371/journal.pone.0055373]
136. Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, duCros P. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ 2012; 90: 540-550 [PMID: 22807600 DOI: 10.2471/BLT.11.097147]
137. Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A, du Cros P. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 2012; 54: 1465-1472 [PMID: 22431808 DOI: 10.1093/cid/cis227]
138. Antaki N, Bibert S, Kebbewar K, Asaad F, Baroudi O, Alideeb S, Hadad M, Abboud D, Sabah H, Bochud PY, Negro F. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J Viral Hepat 2013; 20: 59-64 [PMID: 23231085 DOI: 10.1111/j.1365-2893.2012.01621.x]
139. De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012; 55: 336-342 [PMID: 21932415 DOI: 10.1002/hep.24683]
140. Stättermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Strasser M, Beinhardt S, Datz C, Scherzer TM, Steindl-Munda P, Gschwantler M, Trauner M, Hofer H, Ferenci P. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther 2014; 39: 104-111 [PMID: 24205831 DOI: 10.1111/apt.12547]
141. El Awady MK, Bader El Din NG, Tabll A, El Hosary Y, Abdel Aziz AO, El Khayat H, Salama M, Abdelhafez TH. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients. World J Gastroenterol 2013; 19: 290-298 [PMID: 23345953 DOI: 10.3748/wjg.v19.i2.290]
142. Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Liver Int 2014; 34: 890-895 [PMID: 24102823 DOI: 10.1111/liv.12321]
143. Asselah T, De Muynck S, Broët P, Masliah-Planchon J, Blanluet M, Bièche I, Lapalus M, Martinot-Peignoux M, Lada O, Estrabaud E, Zhang Q, El Ray A, Vidaud D, Ripault MP, Boyer N, Bedossa P, Valla D, Vidaud M, Marcellin P. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527-532 [PMID: 21951981 DOI: 10.1016/j.jhep.2011.09.008]
144. Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M, Hotta H. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load. J Gastroenterol 2012; 47: 1143-1151 [PMID: 22441534 DOI: 10.1007/s00535-012-0578-z]
145. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008; 48: 38-47 [PMID: 18537193 DOI: 10.1002/hep.22339]
146. Yano Y, Seo Y, Miki A, Saito M, Kato H, Hamano K, Oya M, Ouchi S, Fujisawa T, Yamada H, Yamashita Y, Tani S, Hirohata S, Yoon S, Kitajima N, Kitagaki K, Kawara A, Nakashima T, Yu H, Maeda T, Azuma T, El-Shamy A, Hotta H, Hayashi Y. Mutations in non-structural 5A and rapid viral response to pegylated interferon-a-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. Int J Mol Med 2012; 30: 1048-1052 [PMID: 22899224 DOI: 10.3892/ijmm.2012.1093]
147. Moucari R, Ripault MP, Martinot-Peignoux M, Voitot H, Cardoso AC, Stern C, Boyer N, Maylin S, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 1662-1669 [PMID: 19671541 DOI: 10.1136/gut.2009.185074]
148. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol 2011; 17: 5184-5190 [PMID: 22215943 DOI: 10.3748/wjg.v17.i47.5184]
149. Esmat G, El Raziky M, Elsharkawy A, Sabry D, Hassany M, Ahmed A, Assem N, El Kassas M, Doss W. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. J Interferon Cytokine Res 2015; 35: 49-54 [PMID: 25061714 DOI: 10.1089/jir.2014.0060]
150. Doss W, Mohamed MK, Esmat G, El Sayed M, Fontanet A, Cooper S, El Sayed N. Arab Republic of Egypt, Ministry of Health and Population National Committee for the Control of Viral Hepatitis 2008. Available from: URL: http://www.hepnile.org/images/stories/doc/NSP_10_April_2008_final2.pdf
151. El Raziky M, Fathalah WF, El-Akel WA, Salama A, Esmat G, Mabrouk M, Salama RM, Khatab HM. The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study. Hepat Mon 2013; 13: e10069 [PMID: 23922556 DOI: 10.5812/hepatmon.10069]
152. Esmat G, El Kassas M, Hassany M, Gamil M, El Raziky M. Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues. Liver Int 2014; 34 Suppl 1: 24-28 [PMID: 24373075 DOI: 10.1111/liv.12397]
153. Taha AA, El-Ray A, El-Ghannam M, Mounir B. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 2010; 24: 597-602 [PMID: 21037988]
154. Fifi A, Barreto A, Delgado-Borrego A. Optimal management of pediatric hepatitis C infection: a review. Pediatric Health Med Ther 2014; 5: 173-84 [DOI: 10.2147/PHMT.S45256]
155. Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, Murray KF, Narkewicz MR, Rosenthal P, Smith LJ, Schwarz KB, Robuck P, Barton B, González-Peralta RP. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009; 48: 341-347 [PMID: 19242286 DOI: 10.1097/MPG.0b 013e318185998f]
156. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, Wintermeyer P, Jenke A. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-1018 [PMID: 15793840 DOI: 10.1002/hep.20661]
157. Ceci O, Margiotta M, Marello F, Francavilla R, Loizzi P, Francavilla A, Mautone A, Impedovo L, Ierardi E, Mastroianni M, Bettocchi S, Selvaggi L. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 2001; 33: 570-575 [PMID: 11740231]
158. Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000; 31: 751-755 [PMID: 10706568 DOI: 10.1002/hep.510310328]
159. Delgado-Borrego A, Smith L, Jonas MM, Hall CA, Negre B, Jordan SH, Ogrodowicz M, Raza R, Ludwig DA, Miller T, Lipshultz SE, Gonzalez-Peralta R, Chung RT. Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. J Pediatr 2012; 161: 915-921 [PMID: 22765955 DOI: 10.1016/j.jpeds.2012.05.002]
160. González-Peralta RP, Langham MR, Andres JM, Mohan P, Colombani PM, Alford MK, Schwarz KB. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009; 48: 630-635 [PMID: 19412012 DOI: 10.1097/MPG.0b013e318170af04]
161. Karnsakul W, Alford MK, Schwarz KB. Managing pediatric hepatitis C: current and emerging treatment options. Ther Clin Risk Manag 2009; 5: 651-660 [PMID: 19707281]
162. Mohan N, González-Peralta RP, Fujisawa T, Chang MH, Heller S, Jara P, Kelly D, Mieli-Vergani G, Shah U, Murray KF. Chronic hepatitis C virus infection in children. J Pediatr Gastroenterol Nutr 2010; 50: 123-131 [PMID: 20038846 DOI: 10.1097/MPG.0b013e 3181c61995]
163. Shiraki K, Ohto H, Inaba N, Fujisawa T, Tajiri H, Kanzaki S, Matsui A, Morishima T, Goto K, Kimura A, Hino S. Guidelines for care of pregnant women carrying hepatitis C virus and their infants. Pediatr Int 2008; 50: 138-140 [PMID: 18279227 DOI: 10.1111/j.1442-200X.2007.02518.x]
164. Tovo PA, Palomba E, Ferraris G, Principi N, Ruga E, Dallacasa P, Maccabruni A. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children. Clin Infect Dis 1997; 25: 1121-1124 [PMID: 9402369]
165. Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber B, Jonas MM, Mohan P, Balistreri WF, Rosenthal P, Narkewicz MR, Smith LJ, Robuck PR, Barton B. Peginterferon with or without ribavirin for chronic hepatitis C in children and adolescents: final results of the Peds-C trial. Hepatology 2008; 48: 418A [DOI: 10.1002/hep.22641]
166. Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501-507 [PMID: 20189674 DOI: 10.1016/j.jhep.2010.01.016]
167. El Naghi S, Mahmoud F. Study of outcome of naïve and previous nonresponder hepatitis C virus Egyptian children treated with combined therapy of pegylated interferon plus ribavirin. Egyptian Liver Journal 2014; 4: 87-93
168. Ghaffar TY, El Naghy S, El Sebaie H, El Monaiery M, Ghaffar AY. Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr 2009; 76: 895-898 [PMID: 19904504 DOI: 10.1007/s12098-009-0187-x]
169. El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. World J Gastroenterol 2014; 20: 4681-4691 [PMID: 24782620 DOI: 10.3748/wjg.v20.i16.4681]
170. (CDER) USDoHaHSFaDACfDEaR. Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment 2013. Available from: URL: http://www.fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm225333.pdf
171. Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatmentnaïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014; 49: 138-147 [PMID: 24005956 DOI: 10.1007/s00535-013-0875-1]
172. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32 Suppl 1: 88-102 [PMID: 22212578 DOI: 10.1111/j.1478-3231.2011.02699.x]
173. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res 2014; 105: 64-71 [PMID: 24583028 DOI: 10.1016/j.antiviral.2014.02.011]
174. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-2107 [PMID: 23499440 DOI: 10.1016/S0140-6736(13)60247-0]
175. Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol 2014; 12: 728-737 [PMID: 23872239 DOI: 10.1016/j.cgh.2013.06.024]
176. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34 Suppl 1: 69-78 [PMID: 24373081 DOI: 10.1111/liv.12423]
177. Pellicer Corbí M, Matoses Asensio S, Garcia Muñoz C, Ortiz Campos M, Herranz Muñoz C, Fernandez-Pacheco M, Garcia-Valdecasas, Luque Infantes M. PS-071 Telaprevir-induced Stevens-Johnson Syndrome. A case report. Eur J Hosp Pharm-S P 2014; 21(Suppl 1): A172-A173 [DOI: 10.1136/ejhpharm-2013-000436.422]
178. FDA Drug Safety Communication. Serious skin reactions after combination treatment with the Hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin. 2012. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm332731.htm
179. Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-142.e4 [PMID: 24704719 DOI: 10.1053/j.gastro.2014.03.051]
180. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-1929 [PMID: 23907700 DOI: 10.1002/hep.26641]
181. Papastergiou V, Karatapanis S. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World J Clin Cases 2015; 3: 210-220 [PMID: 25789294 DOI: 10.12998/wjcc.v3.i3.210]
182. Gaetano JN. Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug Healthc Patient Saf 2014; 6: 37-45 [PMID: 24729731 DOI: 10.2147/DHPS.S43304]
183. Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, Zoulim F, Grange JD, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, Beumont-Mauviel M, Jessner W. P1319 once-daily simeprevir (tmc435) with peginterferon/ribavirin in treatmentnaive or treatment-experienced chronic hcv genotype 4-infected patients: final results of a phase iii trial. J Hepatol 2014; 60: S535 [DOI: 10.1016/s0168-8278(14)61486-0]
184. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for noncirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-408 [PMID: 23499158 DOI: 10.1016/S1473-3099(13)70033-1]
185. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]
186. Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, Riad J, Mikhail S, Kersey K, Jiang D, Massetto B, Doehle B, Kirby BJ, Knox SJ, McHutchison JG, Symonds WT. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015; 62: 1040-1046 [PMID: 25450208 DOI: 10.1016/j.jhep.2014.10.044]
187. Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2015; 64: 948-956 [PMID: 25080450 DOI: 10.1136/gutjnl-2014-307498]
188. Peter J, Nelson DR. Optimal interferon-free therapy in treatmentexperienced chronic hepatitis C patients. Liver Int 2015; 35 Suppl 1: 65-70 [PMID: 25529089 DOI: 10.1111/liv.12718]
189. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44 [PMID: 23281974 DOI: 10.1056/NEJMoa1208953]
190. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-811 [PMID: 23982366 DOI: 10.1001/jama.2013.109309]
191. SOVALDI US full Prescribing Information. CA: Gilead Sciences, Inc. Foster City. [Accessed 2015 May 1]. Available from: URL: http://hcp.sovaldi.com/
192. Esmat GE, Shiha G, Omar RF, Hassany M, Hammad R, Khairy M, Samir W, Soliman R, Brainard DM, Jiang D, Kersey K, Knox SJ, Massetto B, McHutchison JG, Doss WH. Sofosbuvir plus Ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV infection. The Liver Meeting®, November 7-11, Boston, MA (Poster presentation) no.: 959. 2014
193. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]
194. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2: 30ra32 [PMID: 20445200 DOI: 10.1126/scitranslmed.3000544]
195. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221 [PMID: 24428467 DOI: 10.1056/NEJMoa1306218]
196. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Böcher WO, Mensa FJ. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-639 [PMID: 23944300 DOI: 10.1056/NEJMoa1213557]
197. Hezode C, Marcellin P, Pol S, Hassanein T, Fleischer-Stepniewska K, Baykal T, Wang T, Lovell SS, Pilot-Matias T, Vilchez RA. O58 results from the phase 2 pearl-i study: interferon-free regimens of abt-450/r abt-267 with or without ribavirin in patients with hcv genotype 4 infection. J Hepatol 2014; 60: S24 [DOI: 10.1016/s0168-8278(14)60060-x]
198. Petta S, Craxì A. Current and future HCV therapy: do we still need other anti-HCV drugs? Liver Int 2015; 35 Suppl 1: 4-10 [PMID: 25529081 DOI: 10.1111/liv.12714]
199. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo H, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatmentnaive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015; 15: 645-653 [PMID: 25863559 DOI: 10.1016/S1473-3099(15)70099-X]
200. Hepatitis C Treatments Containing Sofosbuvir in Combination With Another Direct Acting Antiviral Drug: Drug Safety Communication - Serious Slowing of Heart Rate When Used With Antiarrhythmic Drug Amiodarone. 2015. Available from: URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm439662.htm
201. Franciscus A. HCV Advocate Eblast: November 15, 2015. Feds to Medicaid: Stop HCV Treatment Restrictions. The latest news on hepatitis C and coinfection, research, drugs in development, treatment side effects and interferon-free direct antiviral combinations. [Accessed 2015 May 1]. Available from: URL: http://hcvadvocate. org/hcv-advocate-eblast-october-15-2015-2/